Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Characteristics and High-resolution Computed Tomography Findings of 805 Patients with Mild or Moderate Infection from SARS-CoV-2 Omicron Subvariant BA.2

Author(s): Yu-Ning Pan, Meng-Yin Gu, Quan-Liang Mao, Xin-Zhong Ruan, Xian-Feng Du, Xiang Gao, Xue-Qin Chen* and Ai-Jing Li*

Volume 20, 2024

Published on: 07 July, 2023

Article ID: e260423216213 Pages: 8

DOI: 10.2174/1573405620666230426145140

open_access

conference banner
Abstract

Background: COVID-19 is a global pandemic. Currently, the predominant strain is SARS-CoV-2 Omicron subvariant BA.2 in many countries. Understanding its infection characteristics can facilitate clinical management.

Objectives: This study aimed to characterize the clinical, laboratory, and high-resolution computed tomography (HRCT) findings in patients with mild or moderate infection from SARS-CoV-2 Omicron subvariant BA.2.

Methods: We performed a retrospective study on patients infected with SARS-CoV-2 Omicron subvariant BA.2 between April 4th and April 17th, 2022. The clinical characteristics, laboratory features, and HRCT images were reviewed.

Results: A total of 805 patients were included (411 males and 394 females, median age 33 years old). The infection was mild, moderate, severe, and asymptomatic in 490 (60.9%), 37 (4.6%), 0 (0.0%), and 278 (34.5%) patients, respectively. Notably, 186 (23.1%), 96 (11.9%), 265 (32.9%), 11 (3.4%), 7 (0.9%), and 398 (49.4%) patients had fever, cough, throat discomfort, stuffy or runny nose, fatigue, and no complaint, respectively. Furthermore, 162 (20.1%), 332 (41.2%), and 289 (35.9%) patients had decreased white blood cell counts, reduced lymphocytes, and elevated Creactive protein levels, respectively. HRCT revealed pneumonia in 53 (6.6%) patients. The majority of the lung involvements were ground-glass opacity (50, 94.3%) mostly in the subpleural area. The grade of lung injury was mainly mild (90.6%). Short-term follow-ups showed that most patients with pneumonia recovered.

Conclusion: Most patients with mild or moderate infection from SARS-CoV-2 Omicron subvariant BA.2 were adults, with fever and upper respiratory symptoms as the main clinical presentations. Lower respiratory infection was mild, with ground-glass opacity in the subpleural area as the main finding.

Keywords: COVID-19, SARS-COV-2, Omicron variant, BA.2, Computed tomography, Infection.

[1]
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91(1): 157-60.
[PMID: 32191675]
[2]
Organization WHO. 2022. Available from: https://covid19.who.int/
[3]
Mukaigawara M, Hassan I, Fernandes G, King L, Patel J, Sridhar D. An equitable roadmap for ending the COVID-19 pandemic. Nat Med 2022; 28(5): 893-6.
[http://dx.doi.org/10.1038/s41591-022-01787-2] [PMID: 35383313]
[4]
Lundberg AL, Lorenzo-Redondo R, Ozer EA, et al. Has omicron changed the evolution of the pandemic? JMIR Public Health Surveill 2022; 8(1): e35763.
[http://dx.doi.org/10.2196/35763] [PMID: 35072638]
[5]
Kim S, Nguyen TT, Taitt AS, et al. SARS-CoV-2 omicron mutation is faster than the chase: Multiple mutations on spike/ACE2 interaction residues. Immune Netw 2021; 21(6): e38.
[http://dx.doi.org/10.4110/in.2021.21.e38] [PMID: 35036025]
[6]
Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532-46.
[http://dx.doi.org/10.1056/NEJMoa2119451] [PMID: 35249272]
[7]
Gao SJ, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol 2022; 94(4): 1255-6.
[http://dx.doi.org/10.1002/jmv.27491] [PMID: 34850421]
[8]
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): High potential to becoming the next dominating variant. ArXiv [Preprint] 2022.
[PMID: 35169598]
[9]
Lino A, Cardoso MA, Martins-Lopes P, Gonçalves HMR. Omicron-The new SARS-CoV-2 challenge? Rev Med Virol 2022; 32(4): e2358.
[http://dx.doi.org/10.1002/rmv.2358] [PMID: 35445774]
[10]
Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med 2022; 386(15): 1475-7.
[http://dx.doi.org/10.1056/NEJMc2201933] [PMID: 35263535]
[11]
Zhou H, Tada T, Dcosta BM, Landau NR. Neutralization of SARS-CoV-2 omicron BA.2 by therapeutic monoclonal antibodies. bioRxiv 2022. Preprint
[http://dx.doi.org/10.1101/2022.02.15.480166]
[12]
Zarifian A, Ghasemi Nour M, Akhavan Rezayat A, Rahimzadeh Oskooei R, Abbasi B, Sadeghi R. Chest CT findings of coronavirus disease 2019 (COVID-19): A comprehensive meta-analysis of 9907 confirmed patients. Clin Imaging 2021; 70: 101-10.
[http://dx.doi.org/10.1016/j.clinimag.2020.10.035] [PMID: 33142125]
[13]
Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta‐analysis. J Med Virol 2020; 92(10): 1902-14.
[http://dx.doi.org/10.1002/jmv.25884] [PMID: 32293716]
[14]
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623.
[http://dx.doi.org/10.1016/j.tmaid.2020.101623] [PMID: 32179124]
[15]
Diagnosis and treatment protocol for COVID-19 patients (Trial Version 9) Health Care Sci 2022; 1(1): 14-28.
[16]
Sánchez-Oro R, Nuez JT, Martínez-Sanz G. Radiological findings for diagnosis of SARS-CoV-2 pneumonia (COVID-19) Medicina Clínica (English Edition) 2020; 155(1): 36-40.
[17]
Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J 2020; 43(4): 328-33.
[http://dx.doi.org/10.1016/j.bj.2020.04.007] [PMID: 32387617]
[18]
Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res 2022; 209: 112816.
[http://dx.doi.org/10.1016/j.envres.2022.112816] [PMID: 35093310]
[19]
Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593): eabn4947.
[http://dx.doi.org/10.1126/science.abn4947] [PMID: 35289632]
[20]
Zhang Y, Shi L, Cao Y, Chen H, Wang X, Sun G. Wuhan mobile cabin hospital. Medicine (Baltimore) 2021; 100(3): e24077.
[http://dx.doi.org/10.1097/MD.0000000000024077] [PMID: 33546011]
[21]
Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill 2021; 26(50): 2101146.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2101146] [PMID: 34915977]
[22]
Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA 2022; 327(6): 583-4.
[http://dx.doi.org/10.1001/jama.2021.24868] [PMID: 34967859]
[23]
Hui KPY, Ho JCW, Cheung M, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022; 603(7902): 715-20.
[http://dx.doi.org/10.1038/s41586-022-04479-6] [PMID: 35104836]
[24]
Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill 2021; 26(50): 2101147.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2101147] [PMID: 34915975]
[25]
Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci 2021; 25(24): 8012-8.
[PMID: 34982465]
[26]
Kim MK, Lee B, Choi YY, et al. Clinical characteristics of 40 patients Infected With the SARS-CoV-2 omicron variant in Korea. J Korean Med Sci 2022; 37(3): e31.
[http://dx.doi.org/10.3346/jkms.2022.37.e31] [PMID: 35040299]
[27]
CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(50): 1731-4.
[http://dx.doi.org/10.15585/mmwr.mm7050e1] [PMID: 34914670]
[28]
Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a predictor for adverse clinical outcomes in hospitalized patients with COVID-19: A single center retrospective study of 4485 cases. J Clin Med 2022; 11(3): 700.
[http://dx.doi.org/10.3390/jcm11030700] [PMID: 35160150]
[29]
Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. Med Clin (Barc) 2020; 155(4): 143-51.
[http://dx.doi.org/10.1016/j.medcli.2020.05.017]
[30]
Ghahramani S, Tabrizi R, Lankarani KB, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res 2020; 25(1): 30.
[http://dx.doi.org/10.1186/s40001-020-00432-3] [PMID: 32746929]
[31]
Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020; 296(2): E32-40.
[http://dx.doi.org/10.1148/radiol.2020200642] [PMID: 32101510]
[32]
Zuo YY, Uspal WE, Wei T. Airborne transmission of covid-19: aerosol dispersion, lung deposition, and virus-receptor interactions. ACS Nano 2020; 14(12): 16502-24.
[http://dx.doi.org/10.1021/acsnano.0c08484] [PMID: 33236896]
[33]
Silva CIS, Churg A, Müller NL. Hypersensitivity pneumonitis: Spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol 2007; 188(2): 334-44.
[http://dx.doi.org/10.2214/AJR.05.1826] [PMID: 17242239]
[34]
Cho JL, Villacreses R, Nagpal P, et al. Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Radiology 2022; 304(1): 185-92.
[http://dx.doi.org/10.1148/radiol.212170] [PMID: 35289657]
[35]
Waller JV, Lin KK, Diaz MJ, et al. CT presentations of adult and pediatric SARS-CoV-2 patients: A review of early COVID-19 data. Radiologia (Madr) 2021; 63(6): 495-504. [Engl Ed].
[http://dx.doi.org/10.1016/j.rx.2021.04.006]
[36]
Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70(38): 1337-43.
[http://dx.doi.org/10.15585/mmwr.mm7038e1] [PMID: 34555004]

Rights & Permissions Print Cite
Article Metrics
15
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy